NPI: 1669492260 · DALLAS, TX 75204 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 07/20/2006
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHEIF ACCOUNTING OFFICER) |
| NPI Enumeration Date | 07/20/2006 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2021 | 1,731 | $2K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 27 | 14 | $2K |
| 83970 | 105 | 99 | $0.00 | |
| 85048 | 100 | 99 | $0.00 | |
| 83540 | 109 | 99 | $0.00 | |
| 85041 | 100 | 99 | $0.00 | |
| 82108 | 39 | 39 | $0.00 | |
| 85045 | 38 | 38 | $0.00 | |
| 83550 | 109 | 99 | $0.00 | |
| A4657 | Syringe, with or without needle, each | 129 | 127 | $0.00 |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 754 | 58 | $0.00 |
| J1270 | Injection, doxercalciferol, 1 mcg | 85 | 25 | $0.00 |
| 82728 | 108 | 99 | $0.00 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 28 | 12 | $0.00 |